- Home
- UUU vs CNSP Comparison
UUU vs CNSP Comparison
Compare UUU & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$6.17
HOLD
Current Price
$7.26
Company Overview
Basic Information| Metric | UUU | CNSP |
|---|---|---|
| Founded | 1969 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5M | 5.9M |
| IPO Year | 2025 | 2019 |
Fundamental Metrics
Financial Performance| Metric | UUU | CNSP |
|---|---|---|
| Price | $6.17 | $7.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 19.1K | ★ 2.2M |
| Earning Date | 02-19-2026 | 05-15-2026 |
| Dividend Yield | ★ 16.75% | N/A |
| EPS Growth | ★ 229.41 | 8.03 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $23,563,554.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.39 | N/A |
| 52 Week Low | $2.30 | $0.73 |
| 52 Week High | $8.27 | $10.59 |
Technical Indicators
Market Signals| Indicator | UUU | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 54.86 | 74.18 |
| Support Level | $5.54 | $5.62 |
| Resistance Level | $6.43 | $8.73 |
| Average True Range (ATR) | 0.22 | 0.83 |
| MACD | -0.00 | 0.51 |
| Stochastic Oscillator | 70.21 | 56.71 |
Price Performance
Historical Comparison UUU
CNSP
About UUU Universal Security Instruments Inc.
Universal Safety Products Inc is a U.S.-based importer and distributor of home safety devices such as ventilation fans and ground fault circuit interrupters.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.